Government-Owned Inventions; Availability for Licensing, 77413-77414 [E5-8122]
Download as PDF
Federal Register / Vol. 70, No. 250 / Friday, December 30, 2005 / Notices
wwhite on PROD1PC61 with NOTICES
system (TRL–5) entirely based on ciscleaving (trimming) hairpin ribozymes
(triplex system) that release R434 from
long transcripts. Because of the modular
structure of the hairpin ribozyme, the
catalytic domain B can independently
recognize cis or trans targets allowing
the use of the same ribozymes for both
trimming and therapeutic duties. Thus,
this improved system was designed as a
three-ribozymes unit in a canonical
triplex using an inverted cleavage from
one trimming ribozyme.
The Rz434bis system was designed to
use a single R434 ribozyme to catalyze
both trimming and trans-acting
activities. This procedure resulted in a
reduced-size triplex system that uses
R434 catalytic domain to self-excise
itself. RNA from Rz434bis and TRL–5
templates released R434 by a selfprocessing mechanism thus allowing for
the individual activity of multiple transacting ribozymes. Both Rz434bis and
TRL–5 systems produced an increased
cleavage efficiency of HPV–16 target site
nt 410 to 445 when expressed from
linear or circular templates.
Furthermore, duplex Rz434bis and
TRL–5 were more efficient in cleaving
E6 than duplex single R434. The use of
triplex configurations with multi-target
ribozymes will ultimately result in
better in vivo HPV–16 E6/E7 mRNA
degradation. Therefore, implementation
of the triplex systems that significantly
enhance R434 in vitro activity is offered
as an alternative to the antisense
oligodeoxynucleotide treatment of
cervical cancer.
Genomic Nucleic Acid Sequence for
Cyanovirin-N and Signal Peptide
Thereof
Dr. Angela Gronenborn (NIDDK),
U.S. Provisional Application No. 60/
695,599 filed 05 Jul 2005 (HHS
Reference No. E–133–2005/0–US–01),
Licensing Contact: Sally Hu; 301/435–
5606; hus@mail.nih.gov.
The invention provides composition
claims for an isolated or purified
genomic nucleic acid sequence
encoding a CV–N signal peptide, as well
as an isolated or purified nucleic acid
comprising a genomic sequence
encoding a Cyanovirin-N (CV–N)
polypeptide native to the
cyanobacterium species Nostoc
ellipsosporum. The signal peptide can
be used for directing the secretion of
CV–N polypeptide. Further
development of the invention may yield
novel therapies and methods in the
prevention of HIV and other
retroviruses, such as HTLV–1 and 2,
FLV, and treatment of chronic infection
in patients with resistance to current
HIV therapies. The invention also
VerDate Aug<31>2005
18:16 Dec 29, 2005
Jkt 208001
includes vectors and cells comprising
this sequence, methods for producing a
polypeptide, and a method for
inhibiting viral infection in a mammal
by administering a viral-infection
inhibiting amount of the nucleic acid,
vector and/or cell of the invention. It
also provides a method of inhibiting
virus in biological samples or inanimate
objects, and can also be used ex vivo for
virucidal sterilization.
GP41 Inhibitor
G. Marius Clore et al. (NIDDK),
U.S. Provisional Application No. 60/
339,751 filed 17 Dec 2001 (HHS
Reference No. E–252–2001/0–US–01);
PCT Application No. PCT/US02/
40684 filed 17 Dec 2002 (HHS
Reference No. E–252–2001/0–PCT–
02); U.S. Patent Application No. 10/
499,094 filed 14 Jun 2004 (HHS
Reference No. E–252–2001/0–US–03),
Licensing Contact: Susan Ano; 301/435–
5515; anos@mail.nih.gov.
The technology relates to a chimeric
molecule, NCCG-gp41, in which the
internal trimeric helical coiled-coil of
the ectodomain of gp41 is fully exposed
and stabilized by both fusion to a
minimal ectodomain core of gp41 and
by engineered intersubunit disulfide
bonds. NCCG-gp41 inhibits HIV
envelope mediated cell fusion at
nanomolar concentrations with an IC50
of 16 nM. It is proposed that NCCG-gp41
targets the exposed C-terminal region of
the gp41 ectodomain in its pre-hairpin
intermediate state, thereby preventing
the formation of the fusogenic form of
the gp41 ectodomain that comprises a
highly stable trimer of hairpins arranged
in a six-helix bundle. NCCG-gp41 has
potential as (a) an HIV therapeutic agent
that inhibits cell entry; (b) as an AIDS
vaccine and; (c) as a component of a
high throughput screening assay for
small molecule inhibitors of HIV
envelope mediated cell fusion.
Antibodies have been raised against
NCCG-gp41 that inhibit HIV envelope
mediated cell fusion.
This invention is further described in:
J.M. Louis et al., ‘‘Design and properties
of NCCG-gp41, a chimeric gp41
molecule with nanomolar HIV fusion
inhibitory activity,’’ J. Biol. Chem. (2001
Aug 3) 276(31):29485–29489; C.A.
Bewley et al., ‘‘Design of a novel peptide
inhibitor of HIV fusion that disrupts the
internal trimeric coiled-coil of gp41,’’ J.
Biol. Chem. (2002 Apr 19)
277(16):14238–14245; J.M. Louis et al.,
‘‘Covalent trimers of the internal Nterminal trimeric coiled-coil of gp41 and
antibodies directed against them are
potent inhibitors of HIV envelopemediated cell fusion,’’ J. Biol. Chem.
(2003 May 30) 278(22):20278–20285;
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
77413
J.M. Louis et al., ‘‘Characterization and
HIV–1 fusion inhibitory properties of
monoclonal Fabs obtained from a
human non-immune phage library
selected against diverse epitopes of the
ectodomain of HIV–1 gp41,’’ J. Mol.
Biol. (2005 Nov 11) 353(5):945–951.
Dated: December 19, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E5–8121 Filed 12–29–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Molecular Cloning and
Characterization of SNAPIN: A
Synaptic Vesicle Protein Implicated in
Neurotransmitter
Dr. Zu-hang Sheng et al. (NINDS),
HHS Reference No. E–182–1999/0—
Research Tool,
Licensing Contact: Marlene Shinn-Astor;
301/435–4426; shinnm@mail.nih.gov.
Neurotransmitter release is dependent
on a binding complex (designated as
SNAR) of three proteins, synapticvesicle-associated protein
synaptobrevin/VAMP, syntaxin and
SNAP–25 (snaptosome-associated
protein-25) with results in a calcium
E:\FR\FM\30DEN1.SGM
30DEN1
77414
Federal Register / Vol. 70, No. 250 / Friday, December 30, 2005 / Notices
dependent fusion between synaptic
vesicles and the presynaptic terminal.
SNAPIN, a neuron specific protein
found predominately on synaptic
vesicles, binds to the SNAR complex,
most likely to the SNAP–25. Although
the complete function of SNAPIN has
not been determined, it appears to
regulate a step between vesicle
docketing and neurotransmitter release
through its ability to potentiate the
interaction of synaptotagmin with the
SNAREs, which then leads to the final
fusion step triggered by calcium influx
into nerve terminals through voltagedependent calcium channels.
A Mouse With a Targeted Mutation in
the Uncoupling Protein-3 (upc3) Gene
Dr. Marc Reitman et al. (NIDDK),
HHS Reference No. E–031–1999/0—
Research Tool,
Licensing Contact: Marlene ShinnAstor; 301/435–4426;
shinnm@mail.nih.gov.
wwhite on PROD1PC61 with NOTICES
The NIH announces the development
of a transgenic mouse with a targeted
mutation in the ucp3 gene. The ucp3
gene is implicated I the function of
regulating energy metabolism. This
regulatory function is thought to be
accomplished by changing metabolic
efficiency (causing energy expended as
heat rather than used for ADP/ATP
conversion) and/or by participating in
fat metabolism. The mutation should
inactivate the ucp3 function and the
mouse provided a testing vehicle for the
above hypotheses.
If in fact ucp3 is involved in energy
efficiency and/or fat metabolism, then
variation in its sequence or level of
expression may explain some of human
obesity. If ucp3 is involved in fever
generation, it would be of interest in
testing inactivating drugs.
In summary, this mouse model
provides a model for evaluating the role
of ucp3 in obesity, energy efficiency,
and selective use of energy sources (i.e.,
fat vs. carbohydrates), body temperature
regulation, such as fever, or other forms
of stimulated thermogenesis (e.g., by
diet of dietary fat). For example, a drug
candidate thought to act via ucp3
should have no effect in these mice.
Dated: December 19, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E5–8122 Filed 12–29–05; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
18:16 Dec 29, 2005
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section 552b(c)(4)
and 552b(c)(6), Title 5 U.S.C., as
amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Molecular
Oncology 2.
Date: February 21–22, 2006.
Time: 4 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Bethesda North Hotel and
Conference Ctr., 5700 Marinelli Road, North
Bethesda, MD 20852.
Contact Person: Shamala K. Srinivas, PhD,
Scientific Review Administrator, Grants
Review Branch, Division of Extramural
Activities, National Cancer Institute, National
Institutes of Health, 6116 Executive
Boulevard, Room 8133, Bethesda, MD 20892,
301–594–1224.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 22, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–24651 Filed 12–29–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Alternative Medicine; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center
for Complementary and Alternative
Medicine Special Emphasis Panel;
Clinical Science.
Date: February 13–14, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD
20817.
Contact Person: Jeanette M Hosseini,
Scientific Review Administrator,
National Center for Complementary and
Alternative Medicine, 6707 Democracy
Blvd, Suite 401, Bethesda, MD 20892.
(301) 594–9096.
Dated: December 20, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–24662 Filed 12–29–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Eye Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 70, Number 250 (Friday, December 30, 2005)]
[Notices]
[Pages 77413-77414]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-8122]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Molecular Cloning and Characterization of SNAPIN: A Synaptic Vesicle
Protein Implicated in Neurotransmitter
Dr. Zu-hang Sheng et al. (NINDS),
HHS Reference No. E-182-1999/0--Research Tool,
Licensing Contact: Marlene Shinn-Astor; 301/435-4426;
shinnm@mail.nih.gov.
Neurotransmitter release is dependent on a binding complex
(designated as SNAR) of three proteins, synaptic-vesicle-associated
protein synaptobrevin/VAMP, syntaxin and SNAP-25 (snaptosome-associated
protein-25) with results in a calcium
[[Page 77414]]
dependent fusion between synaptic vesicles and the presynaptic
terminal. SNAPIN, a neuron specific protein found predominately on
synaptic vesicles, binds to the SNAR complex, most likely to the SNAP-
25. Although the complete function of SNAPIN has not been determined,
it appears to regulate a step between vesicle docketing and
neurotransmitter release through its ability to potentiate the
interaction of synaptotagmin with the SNAREs, which then leads to the
final fusion step triggered by calcium influx into nerve terminals
through voltage-dependent calcium channels.
A Mouse With a Targeted Mutation in the Uncoupling Protein-3 (upc3)
Gene
Dr. Marc Reitman et al. (NIDDK),
HHS Reference No. E-031-1999/0--Research Tool,
Licensing Contact: Marlene Shinn-Astor; 301/435-4426;
shinnm@mail.nih.gov.
The NIH announces the development of a transgenic mouse with a
targeted mutation in the ucp3 gene. The ucp3 gene is implicated I the
function of regulating energy metabolism. This regulatory function is
thought to be accomplished by changing metabolic efficiency (causing
energy expended as heat rather than used for ADP/ATP conversion) and/or
by participating in fat metabolism. The mutation should inactivate the
ucp3 function and the mouse provided a testing vehicle for the above
hypotheses.
If in fact ucp3 is involved in energy efficiency and/or fat
metabolism, then variation in its sequence or level of expression may
explain some of human obesity. If ucp3 is involved in fever generation,
it would be of interest in testing inactivating drugs.
In summary, this mouse model provides a model for evaluating the
role of ucp3 in obesity, energy efficiency, and selective use of energy
sources (i.e., fat vs. carbohydrates), body temperature regulation,
such as fever, or other forms of stimulated thermogenesis (e.g., by
diet of dietary fat). For example, a drug candidate thought to act via
ucp3 should have no effect in these mice.
Dated: December 19, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E5-8122 Filed 12-29-05; 8:45 am]
BILLING CODE 4140-01-P